Author | Gina Columbus | OncLive

Author | Gina Columbus


FDA Grants Umbralisib Priority Review for Previously Treated MZL

August 13, 2020

The FDA has granted a priority review designation to a new drug application for umbralisib for the treatment of patients with previously treated marginal zone lymphoma who have received at least 1 prior anti-CD20–based treatment.

Sintilimab/Pemetrexed Regimen Significantly Improves PFS in Advanced NSCLC

August 08, 2020

Sintilimab injection plus pemetrexed and platinum-based therapy led to a statistically significant improvement in progression-free survival compared with chemotherapy alone as a first-line treatment for patients with locally advanced or metastatic nonsquamous non–small cell lung cancer.

FDA Approves Belantamab Mafodotin-blmf for Relapsed/Refractory Multiple Myeloma

August 06, 2020

The FDA has approved belantamab mafodotin-blmf (Blenrep) as a treatment for patients with relapsed/refractory multiple myeloma who have received 4 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.